{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T20:14:00Z","timestamp":1773519240417,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2010,2,24]],"date-time":"2010-02-24T00:00:00Z","timestamp":1266969600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1007\/s00259-010-1391-7","type":"journal-article","created":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T15:56:42Z","timestamp":1266940602000},"page":"1279-1290","source":"Crossref","is-referenced-by-count":26,"title":["Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma"],"prefix":"10.1007","volume":"37","author":[{"given":"Ferdinand","family":"Sudbrock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Eschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Berthold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Schicha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,24]]},"reference":[{"key":"1391_CR1","unstructured":"Berger MJ. Distribution of absorbed doses around point sources of electrons and beta particles in water and other media. J Nucl Med 1971;Suppl 5:5\u201323."},{"key":"1391_CR2","unstructured":"Berger MJ, 1992. ESTAR, PSTAR and ASTAR: computer codes for calculating stopping-power and range tables for electrons, protons and helium ions, National Institute of Standards and Technology Report NISTIR 4999. http:\/\/physics.nist.gov\/PhysRefData\/Star\/Text\/contents.html . Accessed 1 Dec 2009."},{"key":"1391_CR3","unstructured":"Berthold F. NB2004 Trial Protocol (confidential), Gesellschaft f\u00fcr p\u00e4diatrische Onkologie und H\u00e4matologie (Society of Pediatric Oncology and Hematology)."},{"key":"1391_CR4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1259\/0007-1285-68-809-481","volume":"68","author":"A Bolster","year":"1995","unstructured":"Bolster A, Hilditch TE, Wheldon TE, Gaze MN, Barrett A. Dosimetric considerations in 131I-MIBG therapy for neuroblastoma in children. Br J Radiol 1995;68:481\u201390.","journal-title":"Br J Radiol"},{"key":"1391_CR5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/cbr.2007.301","volume":"22","author":"SE Buckley","year":"2007","unstructured":"Buckley SE, Gaze MN, Chittenden S, Partridge M, Lancaster D, Pearson A, et al. Dosimetry for fractionated (131)I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results. Cancer Biother Radiopharm 2007;22:105\u201312.","journal-title":"Cancer Biother Radiopharm"},{"key":"1391_CR6","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.2967\/jnumed.109.064469","volume":"50","author":"SE Buckley","year":"2009","unstructured":"Buckley SE, Chittenden SJ, Saran F, Meller ST, Flux GD. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma. J Nucl Med 2009;50:1518\u201324.","journal-title":"J Nucl Med"},{"key":"1391_CR7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1677\/ERC-07-0074","volume":"14","author":"A Chrisoulidou","year":"2007","unstructured":"Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007;14:569\u201385.","journal-title":"Endocr Relat Cancer"},{"key":"1391_CR8","unstructured":"European Commission. Council directive 97\/43\/EURATOM of June 1997 on health protection of individuals against the dangers of ionising radiation in relation to medical exposure. Off J Eur Comm 1997;180:22\u20137."},{"key":"1391_CR9","first-page":"538","volume":"41","author":"JA O\u2019Donoghue","year":"2000","unstructured":"O\u2019Donoghue JA, Sgouros G, Divgi CR, Humm JL. Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry. J Nucl Med 2000;41:538\u201347.","journal-title":"J Nucl Med"},{"key":"1391_CR10","unstructured":"Eckerman KF, Endo A. MIRD: radionuclide data and decay schemes. 2nd ed. Reston: Society of Nuclear Medicine; 2007."},{"key":"1391_CR11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/BF02285457","volume":"18","author":"SL Fielding","year":"1991","unstructured":"Fielding SL, Flower MA, Ackery D, Kemshead JT, Lashford LS, Lewis I. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study. Eur J Nucl Med 1991;18:308\u201316.","journal-title":"Eur J Nucl Med"},{"key":"1391_CR12","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1088\/0031-9155\/41\/10\/006","volume":"41","author":"MA Flower","year":"1996","unstructured":"Flower MA, Fielding SL. Radiation dosimetry for 131I-mIBG therapy of neuroblastoma. Phys Med Biol 1996;41:1933\u201340.","journal-title":"Phys Med Biol"},{"key":"1391_CR13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/108497803321269359","volume":"18","author":"GD Flux","year":"2003","unstructured":"Flux GD, Guy MJ, Papvasileiou P, South C, Chittenden SJ, Flower MA, et al. Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG. Cancer Biother Radiopharm 2003;18:81\u20137.","journal-title":"Cancer Biother Radiopharm"},{"key":"1391_CR14","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00259-007-0652-6","volume":"35","author":"GK Gedik","year":"2008","unstructured":"Gedik GK, Hoefnagel CA, Bais E, Vald\u00e9s Olmos RA. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2008;35:725\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1391_CR15","first-page":"308","volume":"28","author":"CA Hoefnagel","year":"1987","unstructured":"Hoefnagel CA, Vo\u00fbte PA, de Kraker J, Marcuse HR. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med 1987;28:308\u201314.","journal-title":"J Nucl Med"},{"key":"1391_CR16","first-page":"61","volume":"39","author":"CA Hoefnagel","year":"1995","unstructured":"Hoefnagel CA, de Kraker J, Vald\u00e9s Olmos RA, Vo\u00fbte PA. [131I] MIBG as a first line treatment in advanced neuroblastoma. Q J Nucl Med 1995;39:61\u20134.","journal-title":"Q J Nucl Med"},{"key":"1391_CR17","first-page":"773","volume":"25","author":"B Kimmig","year":"1984","unstructured":"Kimmig B, Brandeis WE, Eisenhut M, Bubeck B, Hermann HJ, zum Winkel K. Scintigraphy of a neuroblastoma with I-131 meta-iodobenzylguanidine. J Nucl Med 1984;25:773\u20135.","journal-title":"J Nucl Med"},{"key":"1391_CR18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF00692356","volume":"25","author":"T Klingebiel","year":"1989","unstructured":"Klingebiel T, Treuner J, Ehninger G, Keller KD, Dopfer R, Feine U, et al. [131I]-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects. Cancer Chemother Pharmacol 1989;25:143\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1391_CR19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3413\/nukmed-0087","volume":"47","author":"C Kobe","year":"2008","unstructured":"Kobe C, Eschner W, Sudbrock F, Weber I, Marx K, Dietlein M, et al. Graves\u2019 disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200\u00a0Gy? Nuklearmedizin 2008;47:13\u20137.","journal-title":"Nuklearmedizin"},{"key":"1391_CR20","first-page":"1172","volume":"45","author":"BH Kushner","year":"2004","unstructured":"Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med 2004;45:1172\u201388.","journal-title":"J Nucl Med"},{"key":"1391_CR21","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/BF03350317","volume":"20","author":"KC Loh","year":"1997","unstructured":"Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 1997;20:648\u201358.","journal-title":"J Endocrinol Invest"},{"key":"1391_CR22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/(SICI)1096-911X(199807)31:1<22::AID-MPO5>3.0.CO;2-1","volume":"31","author":"R Mastrangelo","year":"1998","unstructured":"Mastrangelo R, Tornesello A, Mastrangelo S. Role of 131I-Metaiodobenzylguanidine in the treatment of neuroblastoma. Med Pediatr Oncol 1998;31:22\u20136.","journal-title":"Med Pediatr Oncol"},{"key":"1391_CR23","first-page":"1713","volume":"42","author":"K Matthay","year":"2001","unstructured":"Matthay K, Panina C, Huberty J, Price D, Glidden DV, Tang HR, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 2001;42:1713\u201321.","journal-title":"J Nucl Med"},{"key":"1391_CR24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00006231-200104000-00004","volume":"22","author":"MA Monsieurs","year":"2001","unstructured":"Monsieurs MA, Thierens HM, Vral A, Brans B, De Ridder L, Dierckx RA. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours. Nucl Med Commun 2001;22:367\u201374.","journal-title":"Nucl Med Commun"},{"key":"1391_CR25","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s00259-002-0973-4","volume":"29","author":"MA Monsieurs","year":"2002","unstructured":"Monsieurs MA, Brans B, Bacher K, Dierckx R, Thierens H. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans. Eur J Nucl Med Mol Imaging 2002;29:1581\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1391_CR26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3413\/nukmed-0151","volume":"47","author":"L Oehme","year":"2008","unstructured":"Oehme L, D\u00f6rr W, Wust P, Kotzerke J. Influence of time-dose-relationships in therapeutic nuclear medicine applications on biological effectiveness of irradiation: consequences for dosimetry. Nuklearmedizin 2008;47:205\u20139. German.","journal-title":"Nuklearmedizin"},{"key":"1391_CR27","first-page":"1530","volume":"36","author":"AA Bolster","year":"1995","unstructured":"Bolster AA, Hilditch TE, Wheldon TE. Dosimetric models and S factors for radiation doses to the bladder wall in children receiving therapeutic iodine-131-MIBG. J Nucl Med 1995;36:1530\u20132.","journal-title":"J Nucl Med"},{"key":"1391_CR28","first-page":"37","volume":"44","author":"M Schmidt","year":"2005","unstructured":"Schmidt M, Eschner W, Dietlein M, Theissen P, Schicha H. Established nuclear medicine techniques for tumour diagnosis (tumour SPECT): can they still compete with (18)F-FDG-PET? Nuklearmedizin 2005;44:37\u201348. German.","journal-title":"Nuklearmedizin"},{"key":"1391_CR29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-0038-1625111","volume":"45","author":"M Schmidt","year":"2006","unstructured":"Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, et al. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin 2006;45:145\u201351.","journal-title":"Nuklearmedizin"},{"key":"1391_CR30","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.ejca.2008.03.013","volume":"44","author":"M Schmidt","year":"2008","unstructured":"Schmidt M, Simon T, Hero B, Schicha H, Berthold F. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1\u00a0year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer 2008;44:1552\u201358.","journal-title":"Eur J Cancer"},{"key":"1391_CR31","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/mpo.2950150406","volume":"15","author":"B Shapiro","year":"1987","unstructured":"Shapiro B, Gross MD. Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and 123I-MIBG: clinical implication of the use of 123I-MIBG. Med Pediatr Oncol 1987;15:170\u20137.","journal-title":"Med Pediatr Oncol"},{"key":"1391_CR32","first-page":"269","volume":"35","author":"B Shapiro","year":"1991","unstructured":"Shapiro B, Sisson JC, Wieland DM, Mangner TJ, Zempel SM, Mudgett E, et al. Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med 1991;35:269\u201376.","journal-title":"J Nucl Biol Med"},{"key":"1391_CR33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00066-006-1498-8","volume":"182","author":"T Simon","year":"2006","unstructured":"Simon T, Hero B, Bongartz R, Schmidt M, M\u00fcller RP, Berthold F. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children >1\u00a0year with residual local disease. Strahlenther Onkol 2006;182:389\u201394.","journal-title":"Strahlenther Onkol"},{"key":"1391_CR34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF00182305","volume":"21","author":"JC Sisson","year":"1994","unstructured":"Sisson JC, Shapiro B, Hutchinson RJ, Carey JE, Zasadny KR, Zempel SA, et al. Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine. Eur J Nucl Med 1994;21:46\u201352.","journal-title":"Eur J Nucl Med"},{"key":"1391_CR35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1056\/NEJM198107023050103","volume":"305","author":"JC Sisson","year":"1981","unstructured":"Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM, et al. Scintigraphic localization of pheochromocytoma. N Engl J Med 1981;305:12\u20137.","journal-title":"N Engl J Med"},{"key":"1391_CR36","doi-asserted-by":"crossref","first-page":"496","DOI":"10.2967\/jnumed.106.036749","volume":"48","author":"G Sgouros","year":"2007","unstructured":"Sgouros G. Toward patient-friendly cell-level dosimetry. J Nucl Med 2007;48:496\u20137.","journal-title":"J Nucl Med"},{"key":"1391_CR37","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1053\/j.semnuclmed.2008.05.005","volume":"38","author":"MG Stabin","year":"2008","unstructured":"Stabin MG, Brill AB. State of the art in nuclear medicine dose assessment. Semin Nucl Med 2008;38:308\u201320.","journal-title":"Semin Nucl Med"},{"key":"1391_CR38","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-0038-1625121","volume":"45","author":"F Sudbrock","year":"2006","unstructured":"Sudbrock F, Eschner W, Schmidt M, Simon T, Hero B, Schicha H. Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG. Nuklearmedizin 2006;45:254\u201361. German.","journal-title":"Nuklearmedizin"},{"key":"1391_CR39","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3413\/nukmed-0184","volume":"47","author":"F Sudbrock","year":"2008","unstructured":"Sudbrock F, Boldt F, Kobe C, Eschner W, Schicha H. Radiation exposure in the environment of patients after application of radiopharmaceuticals. Part 1: diagnostic procedures. Nuklearmedizin 2008;47:267\u201374. German.","journal-title":"Nuklearmedizin"},{"key":"1391_CR40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3413\/nukmed-0193","volume":"48","author":"F Sudbrock","year":"2009","unstructured":"Sudbrock F, Boldt F, Kobe C, Hammes J, Eschner W, Schicha H. Radiation exposure in the environment of patients after application of radiopharmaceuticals. Part 2: therapeutic procedures. Nuklearmedizin 2009;48:17\u201325. German.","journal-title":"Nuklearmedizin"},{"key":"1391_CR41","first-page":"237","volume":"42","author":"HR Tang","year":"2001","unstructured":"Tang HR, Da Silva AJ, Matthay K, Price DC, Huberty JP, Hawkins RA, et al. Neuroblastoma imaging using a combined CT scanner-scintillation camera and 131I-MIBG. J Nucl Med 2001;42:237\u201347.","journal-title":"J Nucl Med"},{"key":"1391_CR42","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/(SICI)1096-911X(199906)32:6<427::AID-MPO6>3.0.CO;2-T","volume":"32","author":"S Tepmongkol","year":"1999","unstructured":"Tepmongkol S, Heyman S. 131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status. Med Pediatr Oncol 1999;32:427\u201331.","journal-title":"Med Pediatr Oncol"},{"key":"1391_CR43","first-page":"1058","volume":"37","author":"M Tristam","year":"1996","unstructured":"Tristam M, Alaamer AS, Fleming JS, Lewington VJ, Zivanovic MA. Iodine-131-metaiodobenzylguanidine dosimetry in cancer therapy: risk versus benefit. J Nucl Med 1996;37:1058\u201363.","journal-title":"J Nucl Med"},{"key":"1391_CR44","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.apradiso.2004.07.013","volume":"62","author":"P Unak","year":"2005","unstructured":"Unak P, Cetinkaya B. Absorbed dose estimates at the cellular level for 131I. Appl Radiat Isot 2005;62:861\u20139.","journal-title":"Appl Radiat Isot"},{"key":"1391_CR45","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0969-8043(93)90179-E","volume":"44","author":"G Vaidyanathan","year":"1993","unstructured":"Vaidyanathan G, Zalutsky MR. No-carrier-added synthesis of meta-[131I]-iodobenzylguanidine. Appl Radiat Isot 1993;44:621\u201328.","journal-title":"Appl Radiat Isot"},{"key":"1391_CR46","unstructured":"WWW Table of radioactive isotopes. Decay data for iodine-131. http:\/\/nucleardata.nuclear.lu.se\/NuclearData\/toi\/nuclide.asp?iZA=530131 . Accessed 11 Nov 2009."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-010-1391-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-010-1391-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-010-1391-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T16:01:52Z","timestamp":1558713712000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-010-1391-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,24]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["1391"],"URL":"https:\/\/doi.org\/10.1007\/s00259-010-1391-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,24]]}}}